ArticlePloS one2025
Comparison of the effectiveness and safety of vaginal and sublingual low-dose misoprostol versus vaginal dinoprostone for labor ınduction: A retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLabor induction is one of the most common obstetric interventions, yet the optimal pharmacological agent and route of administration remain subjects of ongoing debate. Prostaglandin analogs such as misoprostol and dinoprostone are widely used for cervical ripening and induction; however, evidence comparing their effectiveness and safety across different routes is still limited.
aimThe primary purpose of the study is to evaluate the efficacy and safety of vaginal and sublingual misoprostol and vaginal dinoprostone pessary in labor induction. MATERIALS AND
methodsPatients were divided into three groups based on the labor induction methods used. The first group included patients who received 25 µg vaginal misoprostol for labor induction, the second group included patients who received 25 µg sublingual misoprostol, and the third group included patients who received vaginal dinoprostone pessary. The primary outcome of the study was to evaluate vaginal delivery rates and time from induction to delivery of the fetus. The secondary outcomes of the study were to evaluate cesarean delivery rates, indications for cesarean delivery, first- and fifth-minute Apgar scores, birth weight, gender, amniotic fluid meconium contamination, and admission rates to the neonatal intensive care unit (NICU). The study data were collected from the hospital's automation system and archives. All patients' demographic and obstetric characteristics and maternal and fetal outcomes were recorded in a spreadsheet document (Microsoft Excel™), and statistical analyses were performed using the SPSS 28.0 program.
resultsVaginal delivery rates were higher in the group where vaginal (86,5%) and sublingual misoprostol (85,3%) were applied, and cesarean delivery rates were higher in the group where vaginal dinoprostone pessary (31,6%) was applied (p = 0.000). When the groups were compared according to the duration of labor, no difference was found in the vaginal (523.86 ± 405,92) and sublingual misoprostol (560.15 ± 438,00) groups, while the duration of labor was significantly higher in the dinoprostone pessary group (857.37 ± 558,36) (p = 0.000). Hyperstimulation (6.8%) (p = 0.007) and admission rates to the neonatal intensive care unit (9.1%) (p = 0.004) were higher in the dinoprostone group, and this difference was statistically significant.
conclusionAccording to the results of the study, low-dose vaginal or sublingual misoprostol was found to be more effective and safer than vaginal dinoprostone pessary in labor induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.